The future of cancer care: how can Europe lead the way?

Europe accounts for a tenth of the world’s population, but a quarter of the world’s cancer cases, with over 2.7 million people diagnosed with cancer in the European Union (EU) in 2020. Europe’s Beating Cancer Plan, published in February 2021, was developed to reduce the burden of cancer in the EU, and demonstrated the EU’s commitment to cancer prevention, diagnosis, treatment and care.

One year on from the publication of this plan, and in light of the ongoing impact of the COVID-19 pandemic on cancer services, it is particularly timely to discuss the future of cancer care in Europe.

EU40 is convening a multi-stakeholder panel on 12 March 2022, 10.00-11.00 CET to explore the initiatives driving Europe’s fight against cancer, and key policy priorities to shape the future of cancer care. The event will also explore how the cancer community can collaborate to continue to improve the lives of people living with cancer across Europe. As health systems consider their long-term resilience and sustainability as well as recovery from COVID-19, speakers will consider how European healthcare systems can adopt innovation and deliver the promise of earlier detection, diagnosis, treatment and personalised cancer care.

Confirmed speakers include:

Alessandra Moretti MEP, Member of the European Parliament Special Committee on Beating Cancer
Dr. Bettina Ryll, Founder of the Melanoma Patient Network Europe and Former member of the EU Cancer Mission Board
Dr. Solange Peters, President of European Society for Medical Oncology
Greg Rossi, PhD, Head of Europe and Canada Oncology, AstraZeneca

Commissioner-General Jan Thesleff will provide opening remarks.

Click HERE for more information and registration details.

Live streaming of the discussion will be available via the EU40 YouTube channel.

The event is delivered in partnership with the Swedish Pavilion at EXPO 2020. This event is funded by AstraZeneca, who collaborated with EU40 in the development of the event concept and agenda.